Kyverna Therapeutics, Inc. - Common Stock, par value $0.00001 per share (KYTX)

CUSIP: 501976104

Q1 2025 13F Holders as of 31 Mar 2025

Holder snapshot 7 signals
Share change
-3,088,568
Put/Call ratio
100%
SEC-reported price per share
$1.93
Number of holders
86
Value change
-$8,775,592
Number of buys
39
Open additional details 1 more signal available
Number of sells
40
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
56,833,213

Security key

501976104

Report period

Q1 2025

Institutions

86

Top holders

10

Ownership snapshot

Top reported holders of KYTX - Kyverna Therapeutics, Inc. - Common Stock, par value $0.00001 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
Vida Ventures Advisors, LLC
Disclosed value leader
Vida Ventures Advisors, LLC
Comparable rows
15/15
Latest evidence
31 Dec 2024
13F 3/4/5 Lead comparable stake: 8% Showing 1-6 of 15 holder rows.

Quick read

Vida Ventures Advisors, LLC leads the comparable SEC ownership view at 8%.

15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens Vida Ventures Advisors, LLC's linked filing trail.
Comparable ownership Top 5
Vida Ventures Advisors, LLC 8%
GILEAD SCIENCES, INC. 7.3%
Bain Capital Life Sciences Invest... 5.9%
JPMORGAN CHASE & CO 3.8%
Novo Holdings A/S 3.3%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
Vida Ventures Advisors, LLC
13F
Company
13F
8%
$16,919,476
4,523,924 shares
31 Dec 2024
GILEAD SCIENCES, INC.
13F 3/4/5
Company · 10%+ Owner
7.3%
$15,431,685
4,126,119 shares
31 Dec 2024
Bain Capital Life Sciences Investors, LLC
13F 3/4/5
Company · 10%+ Owner
5.9%
$12,597,704
3,368,370 shares
31 Dec 2024
JPMORGAN CHASE & CO
13F
Company
13F
3.8%
$8,102,474
2,166,437 shares
31 Dec 2024
Novo Holdings A/S
13F
Company
13F
3.3%
$6,919,000
1,850,000 shares
31 Dec 2024
BlackRock, Inc.
13F
Company
13F
2.9%
$6,255,123
1,672,493 shares
31 Dec 2024
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q1 2025

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
86
Shares
25,800,890
Rows available
86
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q1 2025 vs Q4 2024 Across Filers

Q4 2024 holders
87
Q1 2025 holders
86
Holder diff
-1
Investor Q4 2024 Shares Q1 2025 Shares Share Diff Share Chg % Q4 2024 value Q1 2025 value Value change Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .